P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), 2016.

, Eur J Heart Fail, 2016.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, vol.128, pp.1810-52, 2013.

D. S. Lee, P. Gona, I. Albano, M. G. Larson, E. J. Benjamin et al., A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction, Circ Heart Fail, vol.4, pp.36-43, 2011.

M. Vaduganathan, R. B. Patel, A. Michel, S. J. Shah, M. Senni et al., Mode of Death in Heart Failure With Preserved Ejection Fraction, J Am Coll Cardiol, vol.69, pp.556-569, 2017.

S. J. Pocock, C. A. Ariti, J. J. Mcmurray, A. Maggioni, L. Kober et al., Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur Heart J, vol.34, pp.1404-1417, 2013.

A. A. Voors, W. Ouwerkerk, F. Zannad, D. J. Van-veldhuisen, N. J. Samani et al., Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure, Eur J Heart Fail, 2017.

D. Mozaffarian, S. D. Anker, I. Anand, D. T. Linker, M. D. Sullivan et al., Prediction of mode of death in heart failure: the Seattle Heart Failure Model, Circulation, vol.116, pp.392-400, 2007.

R. S. Gardner, F. Ozalp, A. J. Murday, R. Sd, and T. A. Mcdonagh, N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure, Eur Heart J, vol.24, pp.1735-1778, 2003.

A. A. Voors, Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical Trials, JACC Heart Fail, vol.6, pp.257-259, 2018.

A. A. Voors, S. D. Anker, J. G. Cleland, K. Dickstein, G. Filippatos et al., A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF, Eur J Heart Fail, vol.18, pp.716-742, 2016.

J. J. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, pp.803-69

K. Dickstein, A. Cohen-solal, G. Filippatos, J. J. Mcmurray, P. Ponikowski et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur Heart J, vol.29, pp.2388-442, 2008.

J. P. , A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro et al., A new equation to estimate glomerular filtration rate, Ann Intern Med United States, issue.150, pp.604-616, 2009.

J. P. Ferreira, N. Girerd, P. Pellicori, K. Duarte, S. Girerd et al., Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives, BMC Med, vol.14, p.181, 2016.

T. J. Collier, S. J. Pocock, J. J. Mcmurray, F. Zannad, H. Krum et al., The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial, Eur Heart J, vol.34, pp.2823-2832, 2013.

J. P. Ferreira, N. Girerd, J. Gregson, I. Latar, A. Sharma et al., Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation, J Am Coll Cardiol, vol.71, pp.727-735, 2018.

A. Sharma, Z. Hijazi, U. Andersson, S. M. Al-khatib, R. D. Lopes et al., Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation, Circulation, vol.138, pp.1666-1676, 2018.

K. Wakabayashi, N. Ikeda, K. Kajimoto, Y. Minami, T. Keida et al., Trends and predictors of non-cardiovascular death in patients hospitalized for acute heart failure, Int J Cardiol, vol.250, pp.164-170, 2018.

G. M. Felker, R. J. Mentz, J. R. Teerlink, A. A. Voors, P. S. Pang et al., Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study, Eur J Heart Fail, vol.17, pp.1262-70, 2015.

Y. Zhang, R. Zhang, T. An, Y. Huang, X. Guo et al., The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure, J Card Fail, vol.21, pp.51-60, 2015.

R. D. Kociol, P. S. Pang, M. Gheorghiade, G. C. Fonarow, C. M. O'connor et al., Troponin elevation in heart failure prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, vol.56, pp.1071-1079, 2010.

M. Lenz, K. A. Krychtiuk, G. Goliasch, K. Distelmaier, J. Wojta et al., Nterminal pro-brain natriuretic peptide and high-sensitivity troponin T exhibit additive prognostic value for the outcome of critically ill patients, Eur Heart J Acute Cardiovasc Care, p.2048872618768088, 2018.

G. Karthikeyan, R. A. Moncur, O. Levine, D. Heels-ansdell, M. T. Chan et al., Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies, J Am Coll Cardiol, vol.54, pp.1599-606, 2009.

. Ntprobnp,

, Beta-blocker, vol.842

, Legend: BMI, body mass index


, LVEF, left ventricular ejection fraction

. Pci/cabg, percutaneous coronary intervention/coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate

, ACE/ARB, angiotensin converting enzyme/angiotensin receptor blockers

, MRA, mineralocorticoid receptor antagonists